National Coverage Determination (NCD) for Prolotherapy, Joint Sclerotherapy, and Ligamentous Injections with Sclerosing Agents (150.7)

Select the Print Complete Record, Add to Basket or Email Record Buttons to print the record, to add it to your basket or to email the record.

Expand All All sections on the page are Expanded
Collapse All All sections on the page are Collapsed

Tracking Information

Publication Number

100-3

Manual Section Number

150.7

Manual Section Title

Prolotherapy, Joint Sclerotherapy, and Ligamentous Injections with Sclerosing Agents

Version Number

Effective Date of this Version

9/27/1999

Description Information

Benefit Category

Physicians' Services

Please Note: This may not be an exhaustive list of all applicable Medicare benefit categories for this item or service.

Indications and Limitations of Coverage

The medical effectiveness of the above therapies has not been verified by scientifically controlled studies. Accordingly, reimbursement for these modalities should be denied on the ground that they are not reasonable and necessary as required by §1862(a)(1) of the Act.

Transmittal Information

Revision History

9/27/1999 - Issued decision memo maintaining national noncoverage policy.

National Coverage Analyses (NCAs)

This NCD has been or is currently being reviewed under the National Coverage Determination process. The following are existing associations with NCAs, from the National Coverage Analyses database.

Original consideration for Prolotherapy for Chronic Low Back Pain (CAG-00045N) opens in new window

Footer Links